Treatment outcomes in older adolescent and young adult (AYA) patients with newly diagnosed AML.

Authors:
  • JCJ. A. Canner
    J. A. Canner
  • TAT. A. Alonzo
    T. A. Alonzo
  • JFJ. Franklin
    J. Franklin
  • DFD. R. Freyer
    D. R. Freyer
  • AGA. S. Gamis
    A. S. Gamis
  • RGR. B. Gerbing
    R. B. Gerbing
  • BLB. Lange
    B. Lange
  • SMS. Meshinchi
    S. Meshinchi
  • WWW. G. Woods
    W. G. Woods
  • JPJ. P. Perentesis
    J. P. Perentesis
  • JHJ. Horan
    J. Horan
Publisher website
Google Scholar
Abstract
9506 Background: In the CCG 2961 trial for newly diagnosed AML, adolescent and young adult patients (aged 16-21 years, AYA) had inferior survival relative to younger patients. To more broadly define the impact of older age on outcomes in this setting and to identify factors responsible for its effect, we performed an analysis utilizing data from 4 COG trials. Methods: We compiled data from the CCG 2891, CCG 2941, CCG 2961 and AAML03P1 trials. For the 2891 trial, we utilized only the data from patients assigned to the intensively timed treatment arm. We compared the demographics, disease-related characteristics and outcomes of the AYA patients to those of younger patients. Results: The data set included 238 AYA patients (median age=17.2 years) and 1,602 younger patients (median age=6.9 years). There were no significant differences between the groups in race or gender. A greater proportion of the AYA patients were overweight (19.9% vs. 13.2%, p=0.009) and had a matched related donor available (29.0% vs. 21....